Research on Chlamydia infections, including Chlamydia trachomatis

From November 2025

Chlamydia incidence did not increase despite reduced screening in a cohort study (ref: Vanbaelen doi.org/10.1016/j.lanmic.2025.101214/)
Significant cancer risks associated with bacterial STIs were identified in a population-based study (ref: Qureshi doi.org/10.1002/ijc.70215/)
Community pharmacy-based testing for STIs was highly acceptable and effective (ref: d'Entremont-Harris doi.org/10.1016/j.japh.2025.102973/)
DoxyPEP significantly reduced STI incidence in high-risk populations (ref: Palacios doi.org/10.1093/jac/)
Chlamydia co-infections were prevalent and complicated treatment strategies (ref: Lillis doi.org/10.1016/j.ijid.2025.108228/)
Young adults showed strong willingness for Chlamydia vaccination (ref: Chaves doi.org/10.1016/j.vaccine.2025.128027/)
Antimicrobial resistance surveillance is critical as DoxyPEP use increases (ref: Jenks doi.org/10.1071/SH25174/)
Chlamydia muridarum impacts murine models of intestinal inflammation and cancer (ref: Leung doi.org/10.30802/AALAS-JAALAS-25-078/)

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec